Neoadjuvant modified FOLFIRINOX plus nivolumab in borderline-resectable pancreatic ductal adenocarcinoma: a pilot phase 1 trial. - Wainberg ZA; Link JM; Premji A; Zheng S; Srienc M; Hammons M; Kim SE; Li L; Liu Z; Tsvetkova O; Abt ER; Rosen L; et al. (Nature communications, 2026)